Skip to main content

Peptide Therapeutic Deal Benchmarks in Oncology

Median Upfront
$271M
Range: $151M - $383M
Total Deal Value
$1.7B
Range: $1.1B - $2.3B
Royalty Rate
12% - 19.6%
Tiered up to 23.6%
Dev Milestones
$362M
Range: $242M - $485M
Model Your Deal

Market Analysis

Peptide Therapeutic therapies in oncology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 peptide therapeutic asset in oncology is $271M, with total deal values reaching $1.7B. Development milestones average $362M, while regulatory milestones contribute $579M.

The oncology peptide therapeutic landscape is characterized by high competitive intensity with numerous active programs and a rapidly evolving standard of care. ADCs, bispecifics, and radiopharmaceuticals continue to drive premium valuations across solid and hematologic tumors. The recommended deal structure allocates approximately 16% to upfront payments and 84% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for peptide therapeutic oncology deals range from 12% to 19.6% at the base tier, with tiered escalation reaching 16%-23.6% on blockbuster sales. Commercial milestones averaging $507M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a peptide therapeutic oncology licensing deal?
Based on our analysis, Phase 2 peptide therapeutic licensing deals in oncology average $271M in upfront payments, with a range of $151M to $383M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for peptide therapeutic oncology transactions?
The median total deal value for Phase 2 peptide therapeutic assets in oncology is $1.7B, ranging from $1.1B to $2.3B. This includes development milestones ($362M), regulatory milestones ($579M), and commercial milestones ($507M).
What royalty rates are standard for peptide therapeutic deals in oncology?
Base royalty rates for peptide therapeutic oncology transactions range from 12% to 19.6%, with tiered escalations reaching 16%-23.6% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in peptide therapeutic oncology deals?
Peptide Therapeutic oncology deals allocate approximately 84% of total deal value to milestones. Development milestones ($362M) make up the largest share, followed by commercial milestones ($507M) and regulatory milestones ($579M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Oncology

View

Monoclonal Antibody in Oncology

View

Peptide Therapeutic in Neurology

View

Peptide Therapeutic in Immunology & Autoimmune

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included